Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.00%
)
US TECH 100
24,099.57
(
-0.14%
)
Dow Jones
46,993.26
(
0.00%
)
Brent Oil
104.41
(
3.74%
)
Bitcoin
72,390.95
(
-2.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 28
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 60338

Tuesday, 08/19/2008 11:23:56 AM

Tuesday, August 19, 2008 11:23:56 AM

Post# of 257253
VRTX to begin a new phase III study (REALIZE) of telaprevir in HCV treatment failures (it will enroll null responders, partial responders and relapsers).
Telaprevir dose - 750mg, q8h, for 12 weeks + 36 weeks.


http://investors.vrtx.com/releasedetail.cfm?ReleaseID=328603

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today